affiliate disclosure · We earn affiliate commission on some vendor links. Audits, scores, and rankings are independent — vendors do not pay for placement and do not see drafts. read more →
Amino Asylum, Peptide Sciences, and Paradigm Peptides each ceased operations under different circumstances. The signals that preceded each shutdown were public, dated, and ignored.
The public Janoshik test history for retatrutide, semaglutide, and tirzepatide samples between December 2024 and April 2026; FDA-cited court filings for the Paradigm Peptides federal case (December 2025); contemporaneous r/Peptides threads from the 90 days preceding each of the three vendor shutdowns; and post-shutdown reporting on The Peptide Catalog and Muscle and Brawn. This is a forensic synthesis, not a first-hand audit.
Three of the top five US peptide vendors by traffic ceased operations between June 2025 and March 2026 — a roughly four-month cadence at the top of the market. The closures were not the result of a single regulatory action; each ended for different formal reasons. The underlying pattern is what the public data shows in common.
| Vendor | Closed | Cause cited | Pre-warning visible? | |---|---|---|---| | Amino Asylum | June 2025 | FDA raid; SARMs with testosterone | Partially | | Paradigm Peptides | Dec 2025 (plea) | Federal charges; SARMs with testosterone | Yes | | Peptide Sciences | March 6, 2026 | Quality collapse + federal pressure | Yes |
The federal charges that triggered the FDA raid concerned SARMs labeled products that contained testosterone — a controlled substance under 21 U.S.C. § 802(41). The peptide catalog was not the formal subject of the action.
Pre-shutdown signals that were visible:
Pre-shutdown signals that were not visible:
For an outside observer with only public data, the SARM-line discrepancies were a yellow flag for at least three months before the raid. Whether they constituted a predictable signal of a federal action specifically is harder to claim — federal enforcement timing is not observable from outside.
Paradigm's founders pleaded guilty to federal charges in December 2025. The charge pattern was structurally identical to Amino Asylum: products labeled as SARMs that contained controlled substances. The peptide line, again, was not the formal subject of the case.
Pre-shutdown signals that were visible:
The specific learning here is operational, not regulatory: when one vendor in a category is raided for a specific SKU pattern, vendors with visibly similar SKU patterns are an elevated-risk pool for the next 12–18 months. The Paradigm closure five months after Amino Asylum's was predicted, in retrospect, by the structural similarity of their catalogs.
Peptide Sciences was the most-recommended vendor on r/Peptides for most of the 2024–2025 window. Their closure was both the largest by reader impact and the one where the public COA data most clearly anticipated the shutdown.
The Janoshik record for Peptide Sciences retatrutide samples between December 2024 and March 2026 shows 37 tested samples with results that progressively diverged from label claims, including at least one batch that returned a mass-spec identity result inconsistent with retatrutide. The community discussion on r/Peptides escalated through the back half of 2025, with multiple users posting Janoshik QRs showing under-spec purity on what were marketed as premium SKUs.
Federal pressure followed the quality collapse rather than preceding it. The shutdown itself happened with little notice but the trailing data trend was visible to anyone reading the public Janoshik database in mid-2025.
Across the three closures, four signals appeared in some combination:
None of these is a single-shot prediction. In combination, sustained across 60–90 days, they constitute a reasonable risk signal for the audit-side observer.
If you are about to place a recurring order with a vendor:
We do not have access to vendor-internal compliance documentation, non-public sealed court filings, or the full chain-of-custody for the Janoshik samples we cite. The next iteration of this piece will benefit from r/Peptides moderator-side data on which threads were removed for defamation claims — a useful proxy for vendor-side legal pressure that is invisible from the reader-facing forum.
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.